Home › NCT07422584
Cytokine Response to Abdominal Wall Reconstruction
Pilot Study of Systemic Inflammatory and Transcriptomic Responses in Patients Undergoing Open Retromuscular Ventral Hernia Repair
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: Surgical Participants * Adults aged 18 years or older * Scheduled to undergo open retromuscular ventral hernia repair * Able to provide written informed consent Healthy Control Participants * Adults aged 18 years or older * No known inflammatory, autoimmune, or immunologic disease * Able to provide written informed consent Exclusion Criteria: * Emergent or urgent cases * Pregnancy * Chronic systemic steroid use or immunosuppressive therapy * Active infection at the time of enrollment * Known autoimmune or inflammatory disease * End-stage organ failure * Abdominal surgery within the preceding 60 days
About the study
This is a prospective, observational translational study of patients undergoing major abdominal wall reconstruction with primary fascial closure. The project integrates perioperative cytokine profiling, direct measurement of intra-abdominal pressure, and detailed clinical outcomes to define the biologic and physiologic consequences of high-tension closure.
The study includes three cohorts: 1) Healthy controls (N=5), 2) High-tension fascial closure AWR patients (N=10), 3) Low-tension fascial closure AWR patients (N=10). Fascial closure tension will not be altered for the purpose of the study and will be determined by the operating surgeon as part of routine clinical decision-making.
What is being tested
- Not applicable- observational study (other)
Sponsor: Northwestern University · Participants: 25 · Started: Feb 3, 2026
Contact the study team
- Megan Melland-Smith, MD · Phone: 312-907-1414
- Nancy Ly, MD · Phone: 262-455-1560
Official record on ClinicalTrials.gov — NCT07422584
Locations in the U.S.
| Illinois | Northwestern Memorial Hospital, Chicago |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.